15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 1 firms covering Iradimed Co, 1 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $116.00 to $116.00, so the covering firms are broadly aligned. The average target of $116.00 sits 37% above the current $84.43. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.61 next quarter toward $2.41 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS1 ratings
Strong Buy
Strong Buy00%
Buy1100%
Hold00%
Sell00%
Strong Sell00%
Based on 1 analysts giving stock ratings to Iradimed Co.
As of Sep, 1 of 1 firms rate IRMD a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
IRMD EPS & revenue forecast
EPS · NEXT QUARTER
$0.61
Range $0.61 – $0.62 · 2 analysts · +14% YoY
Next period, 2 analysts expect Iradimed Co to earn $0.61 a share (range $0.61 – $0.62), versus $0.54 a year earlier. Full-year consensus is $2.09, growing to $2.41 the year after.
REVENUE · NEXT QUARTER
$25.6M
Range $25.6M – $25.6M · 2 analysts · +13% YoY
Revenue is expected to reach $25.6M (range $25.6M – $25.6M), +12.8% year-over-year. Full-year consensus is $91.2M, rising to $101.0M next year.
Top analysts covering Iradimed Co
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on IRMD.
#1
JW
Jason Wittes
Roth MKM · Rank #311
Buy
$72.00-14.7% to target
Overall win rate
39%
+ Follow
#2
Frank Takkinen
Lake Street · Rank #394
Buy
$120.00+42.1% to target
Overall win rate
26%
+ Follow
#3
IZ
Ilya Zubkov
Freedom Capital Markets
Buy
$116.00+37.4% to target
Coverage
—
+ Follow
#4
IZ
Ilya Zubkov
Freedom Broker
Buy
$116.00+37.4% to target
Coverage
—
+ Follow
#5
KB
Kyle Bauser
Roth Capital
Buy
$120.00+42.1% to target
Coverage
—
+ Follow
IRMD stock forecast FAQ
What is IRMD's average 12-month price target?+
The 1 analysts with a live target average $116.00 for Iradimed Co over the next 12 months, ranging from a $116.00 high to a $116.00 low.
Is IRMD stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 1 analyst ratings, 1 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover IRMD?+
1 analysts have an active rating on Iradimed Co, and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering IRMD?+
Among analysts who currently cover IRMD, Jason Wittes of Roth MKM has the strongest overall Quantellect track record (Rank #311). Their current call is Buy with a $72.00 target.
What is Iradimed Co's projected EPS for next quarter?+
The consensus estimate is $0.61 per share (range $0.61 – $0.62) across 2 analysts. Full-year EPS is projected at $2.09, rising to $2.41 the following year.
How much revenue is Iradimed Co expected to report next quarter?+
Consensus revenue is $25.6M (range $25.6M – $25.6M). Full-year revenue is projected at $91.2M, growing to $101.0M next year.
Have analysts been upgrading or downgrading IRMD lately?+
As of Sep, 1 of 1 firms rate IRMD a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their IRMD calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
